Biontech Value Stock - Dividend - Research Selection
Market price: 196,00 EUR
Biontech SE ADR Fundamental data and company key figures of the share
|Annual reports in EUR|
|Net operating cash flow||-13.474.000|
|Free cash flow||-79.507.000|
|Liabilities & Shareholders equity||2.319.000.000|
|Diluted shares outstanding||246.000.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||58.479.079.424,00 USD|
|Raw Data Source||US GAAP in Millionen EUR|
Description of the company
BioNTech SE, a biotechnology company, develops and markets immunotherapies against cancer and other infectious diseases. The company is involved in the development of FixVac product candidates, including BNT111, which is in the Phase I clinical trial for advanced melanoma. BNT112, which is in Phase I / II trial in prostate cancer; BNT113, which is in Phase I for the treatment of HPV + head and neck cancer; BNT114, which is in Phase I clinical trial for triple negative breast cancer; BNT115 in Phase I Ovarian Cancer Study; and BNT116, which is in a preclinical lane for non-small cell lung cancer. It is also developing neo-antigen-specific immunotherapies such as RO7198457, which is in the Phase II clinical trial for first-line melanoma as well as the Phase I clinical trial for the treatment of multiple solid tumors. Intratumoral mRNA immunotherapy with SAR441000 in Phase I clinical trial for solid tumors; and BNT141 and BNT142 for the treatment of multiple solid tumors. The company is also developing riboCytokines, which include BNT151, BNT152, and BNT152, for several solid tumors. chimeric antigen receptor T cell immunotherapies such as BNT211 for treating multiple solid tumors and BNT212 for treating pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I / II clinical trials for the treatment of multiple solid tumors. It is also developing MVT-5873, an IgG1 monoclonal antibody that is in Phase I / II clinical trials in pancreatic cancer. BNT411, product candidate for low-molecular immunomodulators for solid tumors; and immunotherapies for infectious diseases and protein replacement therapies for rare diseases. The company works with Genentech, Inc .; Sanofi S. A .; Genmab A / S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc .; Shanghai Fosun Pharmaceutical (Group) Co., Ltd .; Regeneron Pharmaceuticals, Inc .; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz.